The following is a summary of “Effect of early administration of fibrinogen replacement therapy in traumatic haemorrhage: a ...

Grifols is gearing up to file for approval of a drug for rare bleeding disorder acquired fibrinogen deficiency (AFD) that could provide a more reliable and easier treatment for patients.

In February, the company reported positive efficacy results from a trial investigating Grifols’ fibrinogen concentrate (FC), BT524, for the treatment of acquired fibrinogen deficiency (AFD).

And the agency also granted a new indication to fibrinogen concentrate (Fibryga) for supplementation in bleeding patients with acquired fibrinogen deficiency, said drugmaker Octapharma.